Health Care & Life Sciences » Pharmaceuticals | Catalyst Biosciences Inc.

Catalyst Biosciences Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
46,705.00
32,623.00
14,762.00
16,945.00
21,561.00
30,055
Depreciation, Depletion & Amortization
547.00
351.00
470.00
389.00
173.00
149
Other Funds
-
3,412.00
-
-
14,318.00
2,722
Funds from Operations
42,823.00
28,115.00
12,858.00
19,308.00
20,507.00
27,184
Changes in Working Capital
2,211.00
6,368.00
6,260.00
836.00
567.00
1,369
Net Operating Cash Flow
40,612.00
34,483.00
19,118.00
18,472.00
19,940.00
28,553
Capital Expenditures
92.00
4.00
272.00
468.00
23.00
Sale of Fixed Assets & Businesses
1,170.00
38.00
23,931.00
890.00
-
Purchase/Sale of Investments
12,331.00
33,822.00
13,698.00
3,404.00
11,229.00
Net Investing Cash Flow
13,409.00
33,856.00
37,357.00
1,308.00
11,252.00
Issuance/Reduction of Debt, Net
851.00
1,136.00
1,132.00
14,340.00
14,318.00
Net Financing Cash Flow
552.00
2,572.00
6,058.00
13,382.00
35,400.00
Net Change in Cash
27,755.00
1,945.00
24,297.00
33,162.00
4,208.00
Free Cash Flow
40,704.00
34,487.00
19,390.00
18,940.00
19,963.00
Other Sources
-
-
-
1,674.00
-
Change in Capital Stock
299.00
296.00
7,190.00
958.00
35,400.00

About Catalyst Biosciences

View Profile
Address
611 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.catalystbiosciences.com
Updated 07/08/2019
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.